x4 pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking and reverse immune suppression, which is fundamental to treating cancer and certain rare, genetic primary immunodeficiency diseases. our oral, small molecule drug candidates inhibit the binding of chemokine cxcl12 to c-x-c receptor type 4 (cxcr4), a receptor-ligand pair that plays an essential role in normal immune surveillance. we are committed to advancing the fields of cancer immunotherapy and genetic immune disorders through innovation and investment in our proprietary clinical and preclinical pipeline. x4’s most advanced product candidate, x4p-001-rd, is in a phase 2/3 study in patients with whim syndrome, a rare genetic, primary immunodeficiency disease. x4p-001-io is currently under investigation in multiple phase 1/2 studies in refractory clear cell renal cell carcinoma (ccrcc) and melanoma. our third program, x4p-002, is in preclinical development and designed specifically for the t
Company profile
Ticker
XFOR, XFOWW, XFORW
Exchange
Website
CEO
Paula Ragan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Arsanis, Inc.
SEC CIK
Corporate docs
Subsidiaries
X4 Pharmaceuticals (Austria) GmbH • X4 Pharmaceuticals Securities Corporation • X4 Therapeutics Inc. ...
XFOR stock data
Latest filings (excl ownership)
8-K
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105
9 May 24
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
7 May 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
8-K
Regulation FD Disclosure
29 Apr 24
8-K
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
29 Apr 24
8-K
Other Events
5 Apr 24
8-K
Regulation FD Disclosure
1 Apr 24
Transcripts
XFOR
Earnings call transcript
2024 Q1
7 May 24
XFOR
Earnings call transcript
2023 Q4
21 Mar 24
XFOR
Earnings call transcript
2023 Q3
9 Nov 23
XFOR
Earnings call transcript
2023 Q2
10 Aug 23
XFOR
Earnings call transcript
2023 Q1
4 May 23
XFOR
Earnings call transcript
2023 Q1
4 May 23
XFOR
Earnings call transcript
2022 Q4
21 Mar 23
XFOR
Earnings call transcript
2022 Q3
3 Nov 22
XFOR
Earnings call transcript
2022 Q2
7 Aug 22
XFOR
Earnings call transcript
2022 Q1
12 May 22
Latest ownership filings
4
Arthur Taveras
11 Mar 24
4
Paula Ragan
11 Mar 24
4
Adam S. Mostafa
11 Mar 24
4
Mary DiBiase
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
4/A
Christophe Arbet-Engels
28 Feb 24
4
Christophe Arbet-Engels
16 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 132.60 mm | 132.60 mm | 132.60 mm | 132.60 mm | 132.60 mm | 132.60 mm |
Cash burn (monthly) | 1.62 mm | (no burn) | 9.07 mm | 11.78 mm | 22.93 mm | 13.53 mm |
Cash used (since last report) | 12.32 mm | n/a | 69.13 mm | 89.74 mm | 174.76 mm | 103.07 mm |
Cash remaining | 120.28 mm | n/a | 63.48 mm | 42.87 mm | -42.16 mm | 29.53 mm |
Runway (months of cash) | 74.4 | n/a | 7.0 | 3.6 | -1.8 | 2.2 |
Institutional ownership, Q4 2023
24.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 12 |
Opened positions | 0 |
Closed positions | 84 |
Increased positions | 1 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 66.77 mm |
Total shares | 40.28 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Growth Equity Opportunities 18 VGE | 15.74 mm | $30.54 mm |
Bain Capital Life Sciences Fund | 12.20 mm | $0.00 |
Empery Asset Management | 4.55 mm | $0.00 |
Biotechnology Value Fund L P | 2.26 mm | $0.00 |
Lincoln Park Capital Fund | 1.81 mm | $3.78 mm |
Millennium Management | 1.66 mm | $0.00 |
Hirschman Orin | 1.51 mm | $3.46 mm |
Flynn James E | 457.50 k | $2.94 mm |
SG Americas Securities | 47.67 k | $40.00 k |
LexAurum Advisors | 16.00 k | $13.42 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Mar 24 | Mostafa Adam S. | Common Stock | Sell | Dispose S | No | No | 0.8828 | 52,500 | 46.35 k | 0 |
11 Mar 24 | Arthur Taveras | Common Stock | Sell | Dispose S | No | No | 0.8818 | 14,235 | 12.55 k | 234,301 |
11 Mar 24 | Ragan Paula | Common Stock | Sell | Dispose S | No | No | 0.8828 | 49,678 | 43.86 k | 765,068 |
11 Mar 24 | Mary DiBiase | Common Stock | Sell | Dispose S | No | No | 0.882 | 15,409 | 13.59 k | 291,752 |
13 Feb 24 | Arbet-Engels Christophe | Stock Appreciation Right Common Stock | Grant | Acquire A | No | No | 0.921 | 475,831 | 438.24 k | 475,831 |
News
X4 Pharmaceuticals Q1 2024 GAAP EPS $(0.26) Misses $(0.16) Estimate
7 May 24
HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $5
30 Apr 24
FDA Approves X4 Pharmaceuticals' Mavorixafor As First Therapy For Rare Immunodeficiency Disorder
29 Apr 24
12 Health Care Stocks Moving In Friday's Intraday Session
26 Apr 24
HC Wainwright & Co. Reiterates Buy on X4 Pharmaceuticals, Maintains $3 Price Target
22 Mar 24
Press releases
X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
13 May 24
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility
9 May 24
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
7 May 24
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
29 Apr 24
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 Apr 24